Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
--Data from Low-Dose Cohort Presented at the 21st Congress of the European Hematology Association Show Durable and Therapeutically Relevant Factor IX (FIX) Expression-- --Median FIX...
-
AMSTERDAM, the Netherlands, May 31, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced financial results for the first quarter ending March 31, 2016,...
-
– Presentation to Include Most Recent Clinical Data from the Five Patient, Low-dose Cohort – – Company to Host Conference Call on Monday, June 13, 2016 at 2:00 pm CET/ 8:00 am...
-
AMSTERDAM, the Netherlands, May 12, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that its management will be presenting at the below listed...
-
AMSTERDAM, The Netherlands, May 9, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the nomination of Jack Kaye to stand for election to uniQure's...
-
AMSTERDAM, the Netherlands, May 9, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the nomination of Jack Kaye to stand for election to uniQure's...
-
AMSTERDAM, the Netherlands, May 9, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the data from several preclinical research programs focused on...
-
AMSTERDAM, the Netherlands, May 3, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Paul Firuta as Chief Commercial Officer. Mr....
-
AMSTERDAM, The Netherlands, April 19, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that six abstracts have been accepted for poster...
-
AMSTERDAM, The Netherlands, April 19, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that six abstracts have been accepted for poster...